Navigation Links
Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
Date:12/31/2008

SAN CARLOS, Calif., Dec. 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it has successfully closed the divestiture of specific Nektar pulmonary delivery assets, technology, and intellectual property to Novartis for $115 million in cash. The transaction was completed on December 31, 2008.

With the closing, Novartis assumes ownership of certain dry powder and liquid pulmonary formulation and manufacturing assets, including capital equipment and manufacturing facility lease obligations. The sale also transferred to Novartis approximately 140 Nektar personnel, as well as certain intellectual property and manufacturing methods, including manufacturing and royalty rights to Novartis' Tobramycin inhalation powder (TIP) program.

Nektar continues to own its Bayer HealthCare-partnered program NKTR-061 (Amikacin Inhale) and royalties from the Ciprofloxacin inhaled powder program (CIP), also partnered with Bayer HealthCare. In addition, Nektar retains its NKTR-063 (inhaled vancomycin) program, as well as all intellectual property specific to inhaled insulin.

JPMorgan acted as exclusive financial advisor to Nektar.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its advanced polymer conjugate technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. For more information on Nektar Therapeutics, please visit http://www.nektar.com.


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Nektar Therapeutics to Webcast R&D Day on November 12th
2. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
4. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
5. Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
6. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
7. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
8. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
9. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
10. West Concludes Agreement with Nektar
11. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... NEW YORK, Dec. 2 Reportlinker.com announces ... available in its catalogue: ,, Neurostimulation ... http://www.reportlinker.com/p0164232/Neurostimulation---A-Global-Market-Perspective.html ,, The world ... base of aging population, and the resultant ...
(Date:12/2/2009)... Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: ... a dose confirmation and dosimetry trial of Cotara® in ... of brain cancer. Cotara is a targeted monoclonal ... potential new treatment for GBM. Cotara specifically targets ...
(Date:12/2/2009)... Cell announced today,a feasibility study evaluating the preclinical ... product which combines technology from Weill,Cornell Medical College ... to,treat inherited anemias such as Cooley,s Anemia. , ... a series of technologies to expand, ex vivo,populations ...
(Date:12/2/2009)... The world is going through,extraordinary times; markets are in ... It turns out that the pharma industry has been,relatively ... a,vacation. , During the midst ... & Johnson inaugurated an R&D center in Shanghai, the ...
Breaking Biology Technology:Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
... Dmitriy Ovcharenko, Rich Jarvis, , ... , ... experimental tool for reducing the expression of specific , ... function analysis, target , validation, ...
... Trace amounts of ribonuclease (RNase) , ... ubiquitous in the laboratory environment--on your skin, in the , ... bare hands or on anything left , ... or eliminate RNase contamination. However, determining which , ...
... , ... Cenix Pre-designed siRNAs to Human, Mouse, and Rat , ... Silencer Validated siRNAs , ... Superior siRNA Design Combined with High , Quality Custom RNA ...
Other Biology Technology:Delivering siRNAs to Difficult Cell Types 2Delivering siRNAs to Difficult Cell Types 3Delivering siRNAs to Difficult Cell Types 4Delivering siRNAs to Difficult Cell Types 5Delivering siRNAs to Difficult Cell Types 6Delivering siRNAs to Difficult Cell Types 7Combat RNase Contamination in the Lab 2Combat RNase Contamination in the Lab 3Combat RNase Contamination in the Lab 4Combat RNase Contamination in the Lab 5IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 2IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 3IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 4IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 5IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 6IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 7IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 8IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 9IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 10
(Date:12/2/2009)... strengthen the evidence that people who smoke cigarettes over ... for developing colorectal cancer, even after adjusting for other ... not to smoke, or to quit as soon as ... vice president emeritus, epidemiology and surveillance research at the ...
(Date:12/2/2009)... cigarette smoking scenes in movies are more likely ... may be part of the acculturation process associated ... , "Our study supports an R-rating for smoking ... implementation of the World Health Organization Framework Convention ...
(Date:12/2/2009)... Smoky Mountain forest,s woodland herb population has shown that ... recover from logging, according to Purdue University research. , ... 80 years ago, the distribution of trillium plants on ... undisturbed areas. Michael Jenkins, a Purdue assistant professor of ...
Breaking Biology News(10 mins):Cigarette smoking increases colorectal cancer risk 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Study finds logging effects vary based on a forest's history, climate 2University of Florida Shands Cancer Center Selects OnCore 28r 29 to Support its Collaborative Research Goals 13034 1University of Florida Shands Cancer Center Selects OnCore 28r 29 to Support its Collaborative Research Goals 13034 2University of Florida Shands Cancer Center Selects OnCore 28r 29 to Support its Collaborative Research Goals 13034 3University of Florida Shands Cancer Center Selects OnCore 28r 29 to Support its Collaborative Research Goals 13034 4University of Florida Shands Cancer Center Selects OnCore 28r 29 to Support its Collaborative Research Goals 13034 5MultiNational Underwriters Is Now HCC Medical Insurance Services 51740 1MultiNational Underwriters Is Now HCC Medical Insurance Services 51740 2 26quot 3BThe Safe 26quot 3B Way To Protect Against The Anguish Of Disaster Recovery 51736 1 26quot 3BThe Safe 26quot 3B Way To Protect Against The Anguish Of Disaster Recovery 51736 2 26quot 3BThe Safe 26quot 3B Way To Protect Against The Anguish Of Disaster Recovery 51736 3
... NY, November 18, 2008 -- Researchers at the University of ... have been used to block and reverse type 1 diabetes ... of the National Academy of Sciences , was led by ... and an expert in the field of autoimmunity. , "The ...
... LAFAYETTE, Ind. - Materials engineers have created a new ... if perfected, might be used for environmental cleanup, water ... last longer than conventional filters for separating oil from ... traits that are usually mutually exclusive. Researchers attached the ...
... German Research Foundation) is intensifying the international ... meeting in Bonn the Grants Committee responsible ... of 13 additional Research Training Groups, 7 ... These enable doctoral researchers to cooperate closely ...
Other Biology News:New filtering technology has environmental, industrial applications 2New filtering technology has environmental, industrial applications 3National and international doctoral training 2National and international doctoral training 3National and international doctoral training 4National and international doctoral training 5National and international doctoral training 6National and international doctoral training 7
One unit is equal to 10Kb (insert DNA + vector). The final cost will increase or decrease according to the final assembled genome size. The price does not include genome annotation....
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Peptide-affinity Purified Polyclonal Antibody to MTR...
Polyclonal Antibody to AGAP1 / Centaurin, gamma 2...
Biology Products: